Daphne Yau

Peroxisome Proliferator–Activated Receptor-α Agonist Treatment in a Transgenic Model of Type 2 Diabetes Reverses the Lipotoxic State and Improves Glucose Homeostasis

Hyunsook Kim, Martin Haluzı́k, Daphne Yau et al. · Diabetes · 2003 · 189 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes

Daphne Yau, Fung-Yee Chan, Derek LeRoith et al. · Diabetologia · 2005 · 75 citations · Full text

Life Sciences, Endocrinology, Physiology +17

Using referral rates for genetic testing to determine the incidence of a rare disease: The minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389

Daphne Yau, Thomas W. Laver, Antonia Dastamani et al. · PLoS ONE · 2020 · 63 citations · Full text

Life Sciences, Genetics, Pediatrics +15

Muscle-Specific Overexpression of CD36 Reverses the Insulin Resistance and Diabetes of MKR Mice

Lisa Héron‐Milhavet, Martin Haluzı́k, Shoshana Yakar et al. · Endocrinology · 2004 · 62 citations

Life Sciences, Endocrinology, Physiology +17

Impaired Glucose-Stimulated Insulin Secretion, Enhanced Intraperitoneal Insulin Tolerance, and Increased β-Cell Mass in Mice Lacking the p110γ Isoform of Phosphoinositide 3-Kinase

Patrick E. MacDonald, Jamie W. Joseph, Daphne Yau et al. · Endocrinology · 2004 · 47 citations · Full text

Life Sciences, Biochemistry, Endocrinology +17